Optinose announced that it has appointed R. John Fletcher to its Board of Directors as a Class III director. Prior to founding Fletcher Spaght, John was a Senior Manager at The Boston Consulting Group, advising a broad range of companies in healthcare and high technology industries.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.08 USD | +0.93% | -2.70% | -16.28% |
May. 20 | OptiNose, Inc. announced that it has received $4.68 million in funding | CI |
May. 14 | Transcript : OptiNose, Inc., Q1 2024 Earnings Call, May 14, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.28% | 155M | |
+40.73% | 734B | |
+32.83% | 591B | |
-6.30% | 350B | |
+15.15% | 315B | |
+4.05% | 276B | |
+15.00% | 238B | |
+9.78% | 206B | |
-5.52% | 204B | |
+6.17% | 161B |
- Stock Market
- Equities
- OPTN Stock
- News OptiNose, Inc.
- Optinose Announces Appointment of R. John Fletcher to its Board of Directors as a Class III Director